Synairgen plc (SNG.L) LSE

Currency In GBp

Synairgen plc

Address

Mailpoint 810

Southampton, SO16 6YD

United Kingdom of Great Britain and Northern Ireland (the)

Phone

44 23 8051 2800

Website

https://www.synairgen.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

October 26, 2004

Key Executives

Name	Title	Pay	Year Born
Richard Marsden	Chief Executive Officer, MD & Executive Director	328,000	1967
Donna Davies	Co-Founder & Member of Scientific Advisory Board	40,000	N/A
Stephen T. Holgate	Co-Founder & Member of Scientific Advisory Board	40,000	1947
Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	40,000	N/A
Joseph Tregonning Colliver	Chief Financial Officer & Executive Director	197,410	1980
Marcin Mankowski	Chief Medical Officer	0	N/A
Victoria Tear	Head of Laboratory	0	N/A
Richard Francis	Senior Vice President and Head of CMC & Quality	0	N/A
Simon William Holden	Company Secretary	0	1976
Jody Brookes	Senior Vice President & Head of Clinical Operations	0	N/A
Gareth E. Walters	Chief Regulatory Officer	0	1959

Description

Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.